The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AstraZeneca's revenues will shrink -6.3% and EPS will drop -23.5%.
The average estimate for revenue is $6.24 billion. On the bottom line, the average EPS estimate is $1.17.
Last quarter, AstraZeneca reported revenue of $6.39 billion. GAAP reported sales were 13% lower than the prior-year quarter's $7.35 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.41. GAAP EPS of $0.81 for Q1 were 36% lower than the prior-year quarter's $1.27 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 80.4%, 160 basis points worse than the prior-year quarter. Operating margin was 30.4%, 850 basis points worse than the prior-year quarter. Net margin was 15.8%, 630 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $26.18 billion. The average EPS estimate is $5.18.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 45 members out of 50 rating the stock outperform, and five members rating it underperform. Among three CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give AstraZeneca a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $47.29.
Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add AstraZeneca to My Watchlist.